# United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/537,269	07/19/2005	Fabio Giannessi	2801-140	1068
	117 7590 07/31/2007 IXON & VANDERHYE, PC		EXAMINER	
901 NORTH GLEBE ROAD, 11TH FLOOR		OOR	CUTLIFF, YATE KAI RENE	
ARLINGTON,	VA 22203		ART UNIT	PAPER NUMBER
			1621	
			MAIL DATE	DELIVERY MODE
			07/31/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
	10/537,269	GIANNESSI ET AL				
Office Action Summary	Examiner	Art Unit				
	·Yate K. Cutliff	1621				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the	correspondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY	/ IS SET TO EXPIRE 3 MONTH	I(S) OR THIRTY (30) DAYS				
WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period w  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION  16(a). In no event, however, may a reply be to the company and will expire SIX (6) MONTHS from the cause the application to become ABANDON	NN. imely filed  n the mailing date of this communication. ED (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 16 M	a <u>y 2007</u> .					
· · · · · · · · · · · · · · · · · · ·						
closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 4	153 O.G. 213.				
Disposition of Claims						
4)⊠ Claim(s) <u>1-5,7-9 and 13-16</u> is/are pending in the application.						
4a) Of the above claim(s) <u>3 and 13-16</u> is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
	6)⊠ Claim(s) <u>1,2 and 7-9</u> is/are rejected.					
7)⊠ Claim(s) <u>4 and 5</u> is/are objected to.  8)□ Claim(s) are subject to restriction and/o	r election requirement					
8) Claim(s) are subject to restriction and/o	r cicolion requirement.					
Application Papers						
9) The specification is objected to by the Examine		·				
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Ex						
Priority under 35 U.S.C. § 119						
12)⊠ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ☐ All b) ☐ Some * c)⊠ None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
•	•					
Attachment(s)  1) Notice of References Cited (PTO-892)	4) Interview Summa	rv (PTO-413)				
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail	Date				
3) Ninformation Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 06/01/2005.	5) Notice of Informa 6) Other:	і насепт Арріісатюл				

Application/Control Number: 10/537,269 Page 2

Art Unit: 1621

## **DETAILED ACTION**

#### Election/Restrictions

1. Applicant's election without traverse of Group I in the reply filed on May 16, 2007 is acknowledged.

2. Claims 1-5, 7-9, and 13 –16 are pending.

Claims 6 and 10-12 have been canceled

Claims 13-16 are withdrawn from consideration as being drawn to the nonelected Invention.

Claims 1, 4, 5 and 7-9, in part embraced in elected subject matter of Group I, and Claim 2 are being prosecuted in this case.

Claims 1, 4, 5 and 7-9, in part, not embraced in the above elected subject matter, and claim 3 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention.

The requirement is still deemed proper.

#### **Priority**

3. Acknowledgment is made of applicant's claim for foreign priority based on an application filed in Italy on December 17, 2002. It is noted, however, that applicant has not filed a certified copy of the IT RM 2002A000625 application as required by 35 U.S.C. 119(b).

## Specification

The abstract of the disclosure is objected to because it was not submitted on a separate sheet. Correction is required. See MPEP § 608.01(b).

## Claim Rejections - 35 USC § 102

5. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 6. Claims 1, 2, 7, 8 and 9 rejected under 35 U.S.C. 102(b) as being anticipated by U.S. Patent 4,731,383 to Erczi et al.

Applicant claims a compound of the following formula:

with n, Q, W, X, Y and Z as defined in claim 1.

Erczi et al. discloses aminoguanidine having the following formula (I):

Erczi et al. anticipates Applicant's claims when the R substituents of Erczi et al. are R1-R3 = halogen, R4 - R5 =  $C_{1-4}$  alkyl, and R7= H. Specifically, when Applicant's n = 0,

Erczi et al. anticipates the claimed invention. Please note that the compound itself reads on the pharmaceutical compositions claims.

## Claim Objections

7. Claims 4 and 5 are objected to for encompassing non-elected subject matter.

#### Allowable Subject Matter

- 8. Compounds where n is equal to 4-7 would be allowable if rewritten in independent form. The following is a statement of reasons for the indication of allowable subject matter: The guanidine derivatives of claim 4 is not taught or suggested by the prior art references.
- 9. As allowable subject matter has been indicated, applicant's reply must either comply with all formal requirements or specifically traverse each requirement not complied with. See 37 CFR 1.111(b) and MPEP § 707.07(a).
- 10. The reference WO 97/23203, cited on From 892 is included as informational.

#### Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Yate K. Cutliff whose telephone number is (571) 272-9067. The examiner can normally be reached on M-TH 8:30 a.m. - 5:00 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler can be reached on (571) 272 - 0871. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/537,269 Page 5

Art Unit: 1621

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Yaté K. Cutliff
Patent Examiner
Art Unit 1609, Group
Technology Center 1600

SAMUEL BARTS
PRIMARY EXAMINER
GROUP 1200